
Does Intel Stock Have Room to Grow?
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2022-12-31 | 2023-12-31 | |
Income Statement | ||||||
Revenue | -- | -- | -- | -- | $8.4M | |
Gross Profit | -- | -- | -- | -- | $5.1M | |
Operating Income | -- | -- | -- | -- | -$8.4M | |
EBITDA | -- | -- | -- | -- | -$18.2M | |
Diluted EPS | -- | -- | -- | -- | -$0.49 |
Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
---|---|---|---|---|---|---|
Balance Sheet | ||||||
Current Assets | -- | -- | -- | -- | $82.6M | |
Total Assets | -- | -- | -- | -- | $96.9M | |
Current Liabilities | -- | -- | -- | -- | $17.9M | |
Total Liabilities | -- | -- | -- | -- | $325.8M | |
Total Equity | -- | -- | -- | -- | -$228.8M | |
Total Debt | -- | -- | -- | -- | -- |
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
Cash Flow Statement | ||||||
Cash Flow Operations | -- | -- | -- | -$26.1M | -$34M | |
Cash From Investing | -- | -- | -- | -$85K | $26.2M | |
Cash From Financing | -- | -- | -- | $101M | -$1.3M | |
Free Cash Flow | -- | -- | -- | -- | -- |
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product include the iLet Bionic Pancreas (iLet). The Company operates as single segment, focused on the development, manufacture and sale of the iLet.
In the current month, BBNX has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The BBNX average analyst price target in the past 3 months is $26.43.
According to analysts, the consensus estimate is that Beta Bionics share price will rise to $26.43 per share over the next 12 months.
Analysts are divided on their view about Beta Bionics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Beta Bionics is a Sell and believe this share price will drop from its current level to $20.00.
The price target for Beta Bionics over the next 1-year time period is forecast to be $26.43 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
According to Wall Street analysts, the consensus rating for Beta Bionics is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
You can purchase shares of Beta Bionics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Beta Bionics shares.
Beta Bionics was last trading at $15.02 per share. This represents the most recent stock quote for Beta Bionics. Yesterday, Beta Bionics closed at $15.02 per share.
In order to purchase Beta Bionics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
For many years, Walmart (NYSE:WMT) has been the world’s largest…
The AI race has heated up significantly but returns on…
Market Cap: $3.3T
P/E Ratio: 36x
Market Cap: $2.8T
P/E Ratio: 32x
Market Cap: $2.6T
P/E Ratio: 36x
Willdan Group [WLDN] is down 3.97% over the past day.
Guardant Health [GH] is up 8.39% over the past day.
Pro-Dex [PDEX] is up 17.54% over the past day.